Viridian Therapeutics, Inc.\DE (VRDN) Retained Earnings (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Retained Earnings history runs 14 years deep, the most recent figure standing at $1.9 billion for Q1 2026.

• In Q1 2026, Retained Earnings rose 279.8% year-over-year to $1.9 billion; the TTM figure through Mar 2026 stood at $1.9 billion (up 279.8% YoY), while the FY2025 annual figure was $1.9 billion, up 19271140.0% from the prior year.
• Retained Earnings for Q1 2026 stood at $1.9 billion, up from $1.9 billion in the prior quarter.
• The five-year high for Retained Earnings was $1.9 billion in Q1 2026, with the low at -$1.2 billion in Q3 2025.
• The 5-year median for Retained Earnings is -$442.4 million (2022), against an average of -$122.1 million.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings sank 310838.85% in 2022, then surged 19271140.0% in 2025.
• Viridian Therapeutics, Inc.\DE's Retained Earnings stood at -$488.2 million in 2022, then jumped by 100.07% to $338000.0 in 2023, then sank by 102.96% to -$10000.0 in 2024, then soared by 19271140.0% to $1.9 billion in 2025, then grew by 1.02% to $1.9 billion in 2026.
• Business Quant data shows VRDN's Retained Earnings at $1.9 billion in Q1 2026, $1.9 billion in Q4 2025, and -$1.2 billion in Q3 2025.